Doctors say there are some good questions to pose before any treatment starts. Customers should ask the person starting the ...

The Business Research Company's The Specific Antiviral Drugs For COVID 19 Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams It will grow to $28.43 billion in 2029 at a ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

Because COVID-19 is caused by a virus, antibiotics cannot be used to treat it. However, Pulia says physicians may feel they ...

Fintel reports that on July 1, 2025, Lake Street initiated coverage of Aytu BioPharma (NasdaqCM:AYTU) with a Buy ...

If you never heard about Andrigolitis before, you’re not alone — it’s one of those bizarre health topics that suddenly pop up in conversations and online ...

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have ...

The Evaluation of Protease Inhibition in COVID-19 (EPIC) programme consists of four phase 2/3 clinical studies in adult patients and was designed to evaluate the safety and efficacy of NMV/r for the ...

The COVID-19 pandemic paused many HIV prevention efforts, which helped fuel last year's rise in new infections. President ...

New York Governor Andrew Cuomo showed optimism about the chloroquine drug and its potential to help those suffering from COVID-19 symptoms.

Blujepa: Most recently, the U.S. Food and Drug Administration (FDA) approved Blujepa (gepotidacin), the first of a new class of drugs for the treatment of uncomplicated urinary tract infections caused ...

EP: 11. Other Investigational Treatment Options for SMA EP: 12. Insurance Considerations for SMA Therapies EP: 13. Optimizing Multidisciplinary Care Approaches for the Future of SMA Management EP: 14.